Presurgical Treatment in HER2-Positive Breast Cancer Achieves Significant Reduction in Disease

Treatment with the HER2-targeted drugs lapatinib and trastuzumab before surgery and chemotherapy led to significant shrinkage or disappearance of the tumors in approximately one-quarter of women with HER2-positive breast cancer. These findings were presented at the 10th European Breast Cancer Conference.

 Oncology Nurse Advisor

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.